PDE4A

(redirected from PDE4)

PDE4A

A gene on chromosome 19p13.2 that encodes a cyclic nucleotide phosphodiesterase, which plays a critical role in signal transduction, regulating intracellular cyclic nucleotide concentrations by hydrolysing the second messenger cAMP to AMP, thereby having a role in regulating physiological processes.
References in periodicals archive ?
OTEZLA (apremilast) 30 mg tablets is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP).
In terms of drug class, the global market has been classified into TNF inhibitors, interleukin inhibitors, PDE4 inhibitors, and others.
In the study, the researchers looked at resveratrol's effect on phosphodiesterase 4 (PDE4), an enzyme influenced by the stress hormone corticosterone, in mice.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study.
Resveratrol is a non-flavonoid polyphenol compound, naturally present on the skin and inside the seeds of grapes as well as berries, offering various health benefits.A TheA (https://www.sciencedirect.com/science/article/pii/S002839081930139X?via%3Dihub) recent study titled, "The antidepressant- and anxiolytic-like effects of resveratrol: Involvement of phosphodiesterase-4D inhibition," was published in Neuropharmacology on July 15 and shed some light on the relationship between wine and stress hormone corticosterone's enzyme called phosphodiesterase 4 (PDE4).A
While research has identified resveratrol to have antidepressant effects, the compound's relationship to phosphodiesterase 4 (PDE4), an enzyme influenced by the stress hormone corticosterone, was unknown.
OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behcet's Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat.
The product is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), particularly for cyclic adenosine monophosphate.
"Targeted Delivery of an Anti-Inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-Drug Conjugate." Molecular Therapy 24, no.
For example, with crisaborole (Eucrisa), the topical phosphodiesterase-4 (PDE4) inhibitor approved in 2016 for mild to moderate AD in patients aged 2 years and up, clear/almost clear rates are 49%-52%, compared with 30%-40% with placebo, a 10%-20% difference.
Coenzyme Q10 Improves Lipid Metabolism and Ameliorates Obesity by Regulating CaMKII-Mediated PDE4 Inhibition.